Venous Thrombosis

45

Pipeline Programs↗

10

Active Trials↗

14

Companies Involved↗

Venous thrombosis is a moderately active landscape with 45 programs across 14 companies. The most active players are Moderna, Pfizer, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 7 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

66/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Moderna

1 program

Pfizer

3 programs

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Alnylam Pharmaceuticals

1 program

Sanofi

5 programs

GSK

2 programs

Analysis

Modality Breakdown

96%

Small molecule

46 of 48 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 100% of 51 pipeline programs.

Analysis

Trial Status

52

clinical trials

Completed21 · 40%

Unknown status10 · 19%

Recruiting8 · 15%

Terminated6 · 12%

Withdrawn5 · 10%

Not yet recruiting2 · 4%

Clinical Trials

Trial Activity

52 trials

Dabigatran Versus Apixaban in Cerebral Venous Thrombosis

Recruiting·KKafrelsheikh University·Phase 3·NCT06551415·200 enrolled

Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis

Recruiting·XXuanwu Hospital, Beijing·Phase 4·NCT07352358·72 enrolled

Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis

Recruiting·KKafrelsheikh University·Phase 3·NCT06551402·200 enrolled

Predictive Value of Modified Caprini Score and D-Dimer in Managing Lower Limb Venous Thrombosis in Cardiothoracic Patients

Recruiting·—·N/A·NCT06729021·112 enrolled

Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)

Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT05711173·150 enrolled

Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis

Recruiting·KKafrelsheikh University·Phase 3·NCT06531122·200 enrolled

Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam

Recruiting·—·N/A·NCT07083609·69 enrolled

Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis

Recruiting·—·N/A·NCT04660747·1,300 enrolled

Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT06841978·306 enrolled

Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06780462·134 enrolled

Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs

Completed· Sanofi logo

Sanofi·Phase 3·NCT00311090·757 enrolled

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis

Completed· Bayer logo

Bayer·Phase 2·NCT02309411·46 enrolled

Study of Rivaroxaban for CeREbral Venous Thrombosis

Completed·UUniversity of British Columbia·Phase 2·NCT03178864·55 enrolled

Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis

Completed·HHospital Universitari de Bellvitge·Phase 4·NCT00689520·241 enrolled

VITRO-Trial. B Vitamins and the Secondary Prevention of Venous Thrombosis

Completed·RRadboud University Medical Center·N/A·NCT00314990·620 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)